National and Kapodistrian University of Athen | Greece
Dr. Laina Ageliki completed her medical studies at the Aristotle University of Thessaloniki in 2012 and holds a Medical Association License in Athens (Protocol No. 188289/2586). She earned an MSc in Cardiopulmonary Resuscitation from the National and Kapodistrian University of Athens (2013–2015, grade A) and is currently pursuing a PhD in Medicine on “The role of proteasome inhibition in vascular function and atherosclerosis in humans” at the University of Athens. Her clinical experience includes serving as a rural service doctor in Tzoumerka, completing residencies in Internal Medicine at “Amalia Fleming” General Hospital (2013–2016) and in Cardiology at the 1st Cardiology Department, Hippokration Hospital, Athens (2018–2023), followed by a scientific associate position in the Electrophysiology Laboratory (2023–2025) and currently a cardiac electrophysiology and pacing fellowship at Clinique Pasteur, Toulouse, France. Dr. Ageliki has actively contributed to multiple clinical trials, including RELAX-HF, PAVE-AF, ReCONSIDER, READAPT, Librexia AF, Protect ICD, and the Enlighten EV-ICD registry. She has received recognition for her research, including the Best Oral Announcement at the 29th Congress of the Hellenic Society of Haematology (2018) and a scholarship from the Hellenic Foundation for Research & Innovation (ELIDEK, 2016). Additionally, she has authored book chapters on cardiovascular topics and contributes to the Greek medical journal HEART and VESSELS.
Featured Publications
"CRT-D or CRT-P: When There Is a Dilemma and How to Solve it"
"Clinical, Electrocardiographic and Echocardiographic Predictors of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation"
"Aggressive Rhythm Control Strategy in Atrial Fibrillation Patients Presenting at the Emergency Department: The HEROMEDICUS Study Design and Initial Results"
"Cardiac mechanics in response to proteasome inhibition: a prospective study"
"Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review"